The stock is currently trading at $34.40, showing positive momentum with a 2.69% gain in post-market trading after closing at $33.50. The stock has been relatively stable with low volatility, trading between $33.42-$34.24 during the regular session.

Fundamental Analysis

The RSI(14) reading of 47.44 indicates neutral momentum, neither overbought nor oversold. The MACD at -0.32 suggests slight bearish momentum in the near term, though this should be viewed in context of the broader trend.

Analyst Sentiment

Recent analyst actions have been largely positive:

Citi maintains Buy rating with $38 target based on promising cabozantinib trial results for NET treatment
JMP Securities maintains Buy rating with $41 target
Morgan Stanley upgraded to Overweight with $40 target
UBS raised target from $30 to $34 while maintaining Hold rating

A key catalyst is approaching - the FDA decision on CABOMETYX by April 3, 2025. The CABINET trial data presented showed significant improvement in progression-free survival for NET patients, which strengthens the bull case.

Recommendation Based on the positive clinical trial results, upcoming FDA catalyst, and strong analyst support, EXEL appears attractively positioned. The stock's current price of $34.40 offers upside potential to the average analyst target of $40-41. The technical indicators suggest a stable base for potential upward movement.

What is price prediction 2025 for EXEL Stock?

Based on the provided data and recent analyst coverage, here's the price prediction for EXEL stock in 2025:

EXEL stock is projected to reach $40-42 by end of 2025, driven by strong sales growth of Cabometyx and promising pipeline developments. Morgan Stanley recently upgraded EXEL to Overweight with a $40 price target, citing "undemanding" valuation. Truist analysts raised their price target to $42, forecasting expanded sales potential for Cabometyx in treating neuroendocrine tumors with estimated peak sales of $700 million.

The stock currently trades at $34.4 with strong technical support around $32.5 based on Fibonacci levels, suggesting limited downside risk while maintaining upward momentum toward the $40+ price targets.

What is surpport and resistant level for EXEL Stock?

The S1 support level for EXEL Stock is $32.5 ,The R1 resistant level for EXEL Stock is $33.98.

What is the current price of EXEL Stock?

As of the end of day on 2025-02-11, the price of EXEL Stock was $33.6.

What is the target price of EXEL Stock?

The target price for EXEL Stock according to analyst rating is 36.65, with the highest price target at 43.00 and the lowest at 25.00. Analysts have a Moderate Buy rating on EXEL Stock overall.

What is the market cap of Exelixis Inc?

The market cap of EXEL is $9.6B.

Is Exelixis Inc (EXEL) overvalued?

Based on the provided data, I'll analyze whether EXEL is overvalued through multiple valuation metrics and recent analyst perspectives.

Valuation Analysis:

Forward P/E of 16.7x for Q3 2024 shows significant improvement from 36.75x in Q1 2024
EV/EBITDA of 9.77x in Q3 2024 decreased from 27.14x in Q1 2024
P/S ratio stable around 3.75x
P/B ratio maintained around 3.26x

Recent Price Movement:

Analyst Consensus: Recent analyst actions show strong positive sentiment:

Citi maintains Buy rating with $38 target price
JMP Securities maintains Buy with $41 target
Morgan Stanley upgraded to Overweight with $40 target
UBS raised target to $34 while maintaining Hold rating

Conclusion in 5 Sentences: EXEL is not overvalued based on its improving valuation metrics and strong growth prospects. The company's forward P/E of 16.7x represents a significant improvement from earlier quarters, suggesting better earnings efficiency. The stock's current trading level around $34.40 offers upside potential given analyst price targets ranging from $34-$41. Strong clinical trial results for cabozantinib in NET treatment and anticipated FDA approval by April 2025 provide solid growth catalysts. The combination of improving fundamentals, positive analyst sentiment, and clear growth drivers indicates the stock is reasonably valued at current levels.

What is Exelixis Inc (EXEL)'s business?

Exelixis, Inc. is an oncology company. The Company is engaged in developing medicines and combination regimens at the forefront of cancer care. It has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma (RCC), for previously treated hepatocellular carcinoma (HCC) and for previously treated, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC), and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer (MTC). The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved the treatment of hypertension.

What is price prediction 2030 for EXEL Stock?

Based on the provided data and analyst reports, here's the price prediction for EXEL stock by 2030:

Exelixis (EXEL) stock is projected to reach $55-60 by 2030, driven by the company's strong oncology portfolio expansion and expected 15% compound annual revenue growth through 2033. Morgan Stanley recently upgraded EXEL to Overweight with a $40 price target, citing undemanding valuation and growth potential in the near term. The company's flagship drug Cabometyx continues showing promising results in new indications, with FDA decisions expected by April 2025, which could significantly boost long-term revenue potential.